Identification of alpha-substituted acylamines as novel, potent, and orally active mGluR5 negative allosteric modulators

Yoshikawa, Keita; Ohyama, Tomofumi; Takahashi, Eiki; Numajiri, Yoshitaka; Konno, Mitsuhiro; Moriyama, Masaki; Takemi, Natsumi; Kunita, Kana; Nishimura, Kazumi; Hayashi, Ryoji

doi:10.1016/j.bmcl.2015.06.008

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, in rodents, the administration of mGluR 5 NAMs reduced the extent of nigrostriatal toxicity in rodents in response to MPTP [146,147], 6-OHDA [148,149], and methamphetamine [150], supporting the use of these drug candidates to exert neuroprotective activity and to slow the progression of neurodegeneration in PD. The relevance of pharmacological blockade of these receptors has inspired the researchers to discover antagonists and negative allosteric modulators [151][152][153][154][155][156][157][158][159][160][161][162][163][164] targeting mGluR 5 .…”

Section: Metabotropic Glutamate Receptorsmentioning

confidence: 99%

Computer-Aided Drug Design Approaches to Study Key Therapeutic Targets in Alzheimer’s Disease

et al. 2017

View full text Add to dashboard Cite

Parkinson's Disease (PD) is a long-term neurodegenative brain disorder that mainly affects the motor system. The causes are still unknown, and even though currently there is no cure, several therapeutic options are available to manage its symptoms. The development of novel anti-parkinsonian agents and an understanding of their proper and optimal use are, indeed, highly demanding. For the last decades, L-3,4-DihydrOxyPhenylAlanine or levodopa (L-DOPA) has been the gold-standard therapy for the symptomatic treatment of motor dysfunctions associated to PD. However, the development of dyskinesias and motor fluctuations (wearing-off and on-off phenomena) associated to long-term L-DOPA replacement therapy have limited its antiparkinsonian efficacy. The investigation for non-dopaminergic therapies has been largely explored as an attempt to counteract the motor side effects associated to dopamine replacement therapy. Being one of the largest cell membrane protein families, G-Protein-Coupled Receptors (GPCRs) have become a relevant target for drug discovery focused in a wide range of therapeutic areas, including Central Nervous System (CNS) diseases. The modulation of specific GPCRs potentially implicated in PD, excluding dopamine receptors, may provide promising non-dopaminergic therapeutic alternatives for symptomatic treatment of PD. In this review, we focused on the impact of specific GPCR subclasses, including dopamine receptors, adenosine receptors, muscarinic acetylcholine receptors, metabotropic glutamate receptors, and 5-hydroxytryptamine receptors, on the pathophysiology of PD and the importance of structure-and ligand-based in silico approaches for the development of small molecules to target these receptors.

show abstract

Section: Metabotropic Glutamate Receptorsmentioning

confidence: 99%

Computer-Aided Drug Design Approaches to Study Key Therapeutic Targets in Alzheimer’s Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease

Lemos

Melo

Preto

et al. 2018

View full text Add to dashboard Cite

Parkinson's Disease (PD) is a long-term neurodegenerative brain disorder that mainly affects the motor system. The causes are still unknown, and even though currently there is no cure, several therapeutic options are available to manage its symptoms. The development of novel antiparkinsonian agents and an understanding of their proper and optimal use are, indeed, highly demanding. For the last decades, L-3,4-DihydrOxyPhenylAlanine or levodopa (L-DOPA) has been the gold-standard therapy for the symptomatic treatment of motor dysfunctions associated to PD. However, the development of dyskinesias and motor fluctuations (wearing-off and on-off phenomena) associated with long-term L-DOPA replacement therapy have limited its antiparkinsonian efficacy. The investigation for non-dopaminergic therapies has been largely explored as an attempt to counteract the motor side effects associated with dopamine replacement therapy. Being one of the largest cell membrane protein families, G-Protein-Coupled Receptors (GPCRs) have become a relevant target for drug discovery focused on a wide range of therapeutic areas, including Central Nervous System (CNS) diseases. The modulation of specific GPCRs potentially implicated in PD, excluding dopamine receptors, may provide promising non-dopaminergic therapeutic alternatives for symptomatic treatment of PD. In this review, we focused on the impact of specific GPCR subclasses, including dopamine receptors, adenosine receptors, muscarinic acetylcholine receptors, metabotropic glutamate receptors, and 5-hydroxytryptamine receptors, on the pathophysiology of PD and the importance of structure- and ligand-based in silico approaches for the development of small molecules to target these receptors.

show abstract

Identification of alpha-substituted acylamines as novel, potent, and orally active mGluR5 negative allosteric modulators

Cited by 2 publications

References 31 publications

Computer-Aided Drug Design Approaches to Study Key Therapeutic Targets in Alzheimer’s Disease

Computer-Aided Drug Design Approaches to Study Key Therapeutic Targets in Alzheimer’s Disease

In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease

Contact Info

Product

Resources

About